nodes	percent_of_prediction	percent_of_DWPC	metapath
Tizanidine—migraine—Prednisone—prostate cancer	0.532	1	CpDpCtD
Tizanidine—CYP1A2—Flutamide—prostate cancer	0.0431	0.347	CbGbCtD
Tizanidine—CYP1A2—Estrone—prostate cancer	0.0312	0.251	CbGbCtD
Tizanidine—CYP1A2—Conjugated Estrogens—prostate cancer	0.0204	0.164	CbGbCtD
Tizanidine—CYP1A2—Estradiol—prostate cancer	0.0179	0.144	CbGbCtD
Tizanidine—CYP1A2—Etoposide—prostate cancer	0.0117	0.0941	CbGbCtD
Tizanidine—Brimonidine—AOX1—prostate cancer	0.00327	0.599	CrCbGaD
Tizanidine—NISCH—Paclitaxel—Cabazitaxel—prostate cancer	0.00276	0.595	CbGdCrCtD
Tizanidine—CYP1A2—urine—prostate cancer	0.00241	0.151	CbGeAlD
Tizanidine—NISCH—prostate gland—prostate cancer	0.00219	0.137	CbGeAlD
Tizanidine—NISCH—urethra—prostate cancer	0.00146	0.0915	CbGeAlD
Tizanidine—NISCH—Paclitaxel—Docetaxel—prostate cancer	0.00114	0.247	CbGdCrCtD
Tizanidine—NISCH—bone marrow—prostate cancer	0.00113	0.0704	CbGeAlD
Tizanidine—ADRA2C—prostate gland—prostate cancer	0.000998	0.0624	CbGeAlD
Tizanidine—NISCH—testis—prostate cancer	0.000963	0.0602	CbGeAlD
Tizanidine—ADRA2C—seminal vesicle—prostate cancer	0.000844	0.0528	CbGeAlD
Tizanidine—ADRA2A—prostate gland—prostate cancer	0.000797	0.0498	CbGeAlD
Tizanidine—Clonidine—SLC22A3—prostate cancer	0.000743	0.136	CrCbGaD
Tizanidine—NISCH—Podofilox—Etoposide—prostate cancer	0.000735	0.159	CbGdCrCtD
Tizanidine—NISCH—lymph node—prostate cancer	0.000698	0.0436	CbGeAlD
Tizanidine—ADRA2C—renal system—prostate cancer	0.00068	0.0425	CbGeAlD
Tizanidine—ADRA2A—seminal vesicle—prostate cancer	0.000674	0.0421	CbGeAlD
Tizanidine—ADRA2C—urethra—prostate cancer	0.000668	0.0418	CbGeAlD
Tizanidine—CYP1A2—renal system—prostate cancer	0.00059	0.0369	CbGeAlD
Tizanidine—ADRA2A—urethra—prostate cancer	0.000533	0.0333	CbGeAlD
Tizanidine—Clonidine—SLC22A1—prostate cancer	0.000533	0.0977	CrCbGaD
Tizanidine—ADRA2C—testis—prostate cancer	0.00044	0.0275	CbGeAlD
Tizanidine—Clonidine—CYP3A5—prostate cancer	0.00043	0.0789	CrCbGaD
Tizanidine—ADRA2A—testis—prostate cancer	0.000351	0.0219	CbGeAlD
Tizanidine—ADRA2C—lymph node—prostate cancer	0.000319	0.0199	CbGeAlD
Tizanidine—Clonidine—CYP1A1—prostate cancer	0.000292	0.0535	CrCbGaD
Tizanidine—ADRA2A—lymph node—prostate cancer	0.000254	0.0159	CbGeAlD
Tizanidine—Clonidine—CYP3A4—prostate cancer	0.000186	0.0341	CrCbGaD
Tizanidine—Urticaria—Etoposide—prostate cancer	4.46e-05	0.00018	CcSEcCtD
Tizanidine—Haemoglobin—Epirubicin—prostate cancer	4.45e-05	0.000179	CcSEcCtD
Tizanidine—Jaundice—Doxorubicin—prostate cancer	4.45e-05	0.000179	CcSEcCtD
Tizanidine—Malaise—Prednisone—prostate cancer	4.45e-05	0.000179	CcSEcCtD
Tizanidine—Shock—Capecitabine—prostate cancer	4.44e-05	0.000179	CcSEcCtD
Tizanidine—Rhinitis—Epirubicin—prostate cancer	4.44e-05	0.000179	CcSEcCtD
Tizanidine—Abdominal pain—Etoposide—prostate cancer	4.44e-05	0.000179	CcSEcCtD
Tizanidine—Body temperature increased—Etoposide—prostate cancer	4.44e-05	0.000179	CcSEcCtD
Tizanidine—Conjunctivitis—Doxorubicin—prostate cancer	4.44e-05	0.000179	CcSEcCtD
Tizanidine—Nervous system disorder—Capecitabine—prostate cancer	4.43e-05	0.000179	CcSEcCtD
Tizanidine—Vertigo—Prednisone—prostate cancer	4.43e-05	0.000179	CcSEcCtD
Tizanidine—Hepatitis—Epirubicin—prostate cancer	4.43e-05	0.000179	CcSEcCtD
Tizanidine—Haemorrhage—Epirubicin—prostate cancer	4.43e-05	0.000179	CcSEcCtD
Tizanidine—Thrombocytopenia—Capecitabine—prostate cancer	4.42e-05	0.000178	CcSEcCtD
Tizanidine—Syncope—Prednisone—prostate cancer	4.42e-05	0.000178	CcSEcCtD
Tizanidine—Tachycardia—Capecitabine—prostate cancer	4.41e-05	0.000178	CcSEcCtD
Tizanidine—Pharyngitis—Epirubicin—prostate cancer	4.4e-05	0.000177	CcSEcCtD
Tizanidine—Skin disorder—Capecitabine—prostate cancer	4.39e-05	0.000177	CcSEcCtD
Tizanidine—Sweating—Doxorubicin—prostate cancer	4.38e-05	0.000176	CcSEcCtD
Tizanidine—Urinary tract disorder—Epirubicin—prostate cancer	4.37e-05	0.000176	CcSEcCtD
Tizanidine—Hyperhidrosis—Capecitabine—prostate cancer	4.37e-05	0.000176	CcSEcCtD
Tizanidine—Hypotension—Docetaxel—prostate cancer	4.36e-05	0.000176	CcSEcCtD
Tizanidine—Haematuria—Doxorubicin—prostate cancer	4.35e-05	0.000175	CcSEcCtD
Tizanidine—Connective tissue disorder—Epirubicin—prostate cancer	4.35e-05	0.000175	CcSEcCtD
Tizanidine—Urethral disorder—Epirubicin—prostate cancer	4.34e-05	0.000175	CcSEcCtD
Tizanidine—Loss of consciousness—Prednisone—prostate cancer	4.33e-05	0.000175	CcSEcCtD
Tizanidine—Hepatobiliary disease—Doxorubicin—prostate cancer	4.32e-05	0.000174	CcSEcCtD
Tizanidine—Nausea—Estradiol—prostate cancer	4.3e-05	0.000173	CcSEcCtD
Tizanidine—Vomiting—Mitoxantrone—prostate cancer	4.29e-05	0.000173	CcSEcCtD
Tizanidine—Sinusitis—Doxorubicin—prostate cancer	4.28e-05	0.000173	CcSEcCtD
Tizanidine—Convulsion—Prednisone—prostate cancer	4.27e-05	0.000172	CcSEcCtD
Tizanidine—Agranulocytosis—Doxorubicin—prostate cancer	4.26e-05	0.000172	CcSEcCtD
Tizanidine—Hypertension—Prednisone—prostate cancer	4.26e-05	0.000172	CcSEcCtD
Tizanidine—Rash—Mitoxantrone—prostate cancer	4.25e-05	0.000172	CcSEcCtD
Tizanidine—Dermatitis—Mitoxantrone—prostate cancer	4.25e-05	0.000171	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.25e-05	0.000171	CcSEcCtD
Tizanidine—Hypotension—Capecitabine—prostate cancer	4.22e-05	0.00017	CcSEcCtD
Tizanidine—Arthralgia—Prednisone—prostate cancer	4.2e-05	0.000169	CcSEcCtD
Tizanidine—Paraesthesia—Docetaxel—prostate cancer	4.19e-05	0.000169	CcSEcCtD
Tizanidine—Erythema multiforme—Epirubicin—prostate cancer	4.19e-05	0.000169	CcSEcCtD
Tizanidine—Anxiety—Prednisone—prostate cancer	4.18e-05	0.000169	CcSEcCtD
Tizanidine—Bradycardia—Doxorubicin—prostate cancer	4.17e-05	0.000168	CcSEcCtD
Tizanidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.17e-05	0.000168	CcSEcCtD
Tizanidine—Dyspnoea—Docetaxel—prostate cancer	4.16e-05	0.000168	CcSEcCtD
Tizanidine—Somnolence—Docetaxel—prostate cancer	4.15e-05	0.000167	CcSEcCtD
Tizanidine—Discomfort—Prednisone—prostate cancer	4.15e-05	0.000167	CcSEcCtD
Tizanidine—Hypersensitivity—Etoposide—prostate cancer	4.14e-05	0.000167	CcSEcCtD
Tizanidine—Tinnitus—Epirubicin—prostate cancer	4.13e-05	0.000166	CcSEcCtD
Tizanidine—Haemoglobin—Doxorubicin—prostate cancer	4.12e-05	0.000166	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.11e-05	0.000166	CcSEcCtD
Tizanidine—Cardiac disorder—Epirubicin—prostate cancer	4.11e-05	0.000166	CcSEcCtD
Tizanidine—Rhinitis—Doxorubicin—prostate cancer	4.11e-05	0.000166	CcSEcCtD
Tizanidine—Dyspepsia—Docetaxel—prostate cancer	4.11e-05	0.000166	CcSEcCtD
Tizanidine—Haemorrhage—Doxorubicin—prostate cancer	4.1e-05	0.000165	CcSEcCtD
Tizanidine—Hepatitis—Doxorubicin—prostate cancer	4.1e-05	0.000165	CcSEcCtD
Tizanidine—Pharyngitis—Doxorubicin—prostate cancer	4.07e-05	0.000164	CcSEcCtD
Tizanidine—Paraesthesia—Capecitabine—prostate cancer	4.06e-05	0.000164	CcSEcCtD
Tizanidine—Urinary tract disorder—Doxorubicin—prostate cancer	4.05e-05	0.000163	CcSEcCtD
Tizanidine—Asthenia—Etoposide—prostate cancer	4.03e-05	0.000162	CcSEcCtD
Tizanidine—Connective tissue disorder—Doxorubicin—prostate cancer	4.03e-05	0.000162	CcSEcCtD
Tizanidine—Dyspnoea—Capecitabine—prostate cancer	4.03e-05	0.000162	CcSEcCtD
Tizanidine—Anaphylactic shock—Prednisone—prostate cancer	4.02e-05	0.000162	CcSEcCtD
Tizanidine—Oedema—Prednisone—prostate cancer	4.02e-05	0.000162	CcSEcCtD
Tizanidine—Fatigue—Docetaxel—prostate cancer	4.02e-05	0.000162	CcSEcCtD
Tizanidine—Angiopathy—Epirubicin—prostate cancer	4.02e-05	0.000162	CcSEcCtD
Tizanidine—Urethral disorder—Doxorubicin—prostate cancer	4.02e-05	0.000162	CcSEcCtD
Tizanidine—Nausea—Mitoxantrone—prostate cancer	4.01e-05	0.000162	CcSEcCtD
Tizanidine—Immune system disorder—Epirubicin—prostate cancer	4e-05	0.000161	CcSEcCtD
Tizanidine—Infection—Prednisone—prostate cancer	4e-05	0.000161	CcSEcCtD
Tizanidine—Mediastinal disorder—Epirubicin—prostate cancer	3.99e-05	0.000161	CcSEcCtD
Tizanidine—Constipation—Docetaxel—prostate cancer	3.99e-05	0.000161	CcSEcCtD
Tizanidine—Dyspepsia—Capecitabine—prostate cancer	3.98e-05	0.00016	CcSEcCtD
Tizanidine—Pruritus—Etoposide—prostate cancer	3.97e-05	0.00016	CcSEcCtD
Tizanidine—Shock—Prednisone—prostate cancer	3.96e-05	0.00016	CcSEcCtD
Tizanidine—Arrhythmia—Epirubicin—prostate cancer	3.96e-05	0.00016	CcSEcCtD
Tizanidine—Nervous system disorder—Prednisone—prostate cancer	3.95e-05	0.000159	CcSEcCtD
Tizanidine—Tachycardia—Prednisone—prostate cancer	3.93e-05	0.000158	CcSEcCtD
Tizanidine—Alopecia—Epirubicin—prostate cancer	3.91e-05	0.000158	CcSEcCtD
Tizanidine—Skin disorder—Prednisone—prostate cancer	3.91e-05	0.000158	CcSEcCtD
Tizanidine—Fatigue—Capecitabine—prostate cancer	3.89e-05	0.000157	CcSEcCtD
Tizanidine—Hyperhidrosis—Prednisone—prostate cancer	3.89e-05	0.000157	CcSEcCtD
Tizanidine—Mental disorder—Epirubicin—prostate cancer	3.88e-05	0.000156	CcSEcCtD
Tizanidine—Erythema multiforme—Doxorubicin—prostate cancer	3.87e-05	0.000156	CcSEcCtD
Tizanidine—Constipation—Capecitabine—prostate cancer	3.86e-05	0.000156	CcSEcCtD
Tizanidine—Feeling abnormal—Docetaxel—prostate cancer	3.84e-05	0.000155	CcSEcCtD
Tizanidine—Diarrhoea—Etoposide—prostate cancer	3.84e-05	0.000155	CcSEcCtD
Tizanidine—Tinnitus—Doxorubicin—prostate cancer	3.82e-05	0.000154	CcSEcCtD
Tizanidine—Gastrointestinal pain—Docetaxel—prostate cancer	3.81e-05	0.000154	CcSEcCtD
Tizanidine—Cardiac disorder—Doxorubicin—prostate cancer	3.8e-05	0.000153	CcSEcCtD
Tizanidine—Flatulence—Epirubicin—prostate cancer	3.8e-05	0.000153	CcSEcCtD
Tizanidine—Tension—Epirubicin—prostate cancer	3.78e-05	0.000153	CcSEcCtD
Tizanidine—Nervousness—Epirubicin—prostate cancer	3.74e-05	0.000151	CcSEcCtD
Tizanidine—Back pain—Epirubicin—prostate cancer	3.73e-05	0.00015	CcSEcCtD
Tizanidine—Feeling abnormal—Capecitabine—prostate cancer	3.72e-05	0.00015	CcSEcCtD
Tizanidine—Angiopathy—Doxorubicin—prostate cancer	3.72e-05	0.00015	CcSEcCtD
Tizanidine—Dizziness—Etoposide—prostate cancer	3.71e-05	0.00015	CcSEcCtD
Tizanidine—Muscle spasms—Epirubicin—prostate cancer	3.71e-05	0.000149	CcSEcCtD
Tizanidine—Immune system disorder—Doxorubicin—prostate cancer	3.7e-05	0.000149	CcSEcCtD
Tizanidine—Gastrointestinal pain—Capecitabine—prostate cancer	3.69e-05	0.000149	CcSEcCtD
Tizanidine—Mediastinal disorder—Doxorubicin—prostate cancer	3.69e-05	0.000149	CcSEcCtD
Tizanidine—Abdominal pain—Docetaxel—prostate cancer	3.69e-05	0.000149	CcSEcCtD
Tizanidine—Body temperature increased—Docetaxel—prostate cancer	3.69e-05	0.000149	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Prednisone—prostate cancer	3.67e-05	0.000148	CcSEcCtD
Tizanidine—Arrhythmia—Doxorubicin—prostate cancer	3.66e-05	0.000148	CcSEcCtD
Tizanidine—Vision blurred—Epirubicin—prostate cancer	3.63e-05	0.000147	CcSEcCtD
Tizanidine—Alopecia—Doxorubicin—prostate cancer	3.62e-05	0.000146	CcSEcCtD
Tizanidine—Paraesthesia—Prednisone—prostate cancer	3.61e-05	0.000146	CcSEcCtD
Tizanidine—Mental disorder—Doxorubicin—prostate cancer	3.59e-05	0.000145	CcSEcCtD
Tizanidine—Urticaria—Capecitabine—prostate cancer	3.59e-05	0.000145	CcSEcCtD
Tizanidine—Ill-defined disorder—Epirubicin—prostate cancer	3.58e-05	0.000144	CcSEcCtD
Tizanidine—Body temperature increased—Capecitabine—prostate cancer	3.57e-05	0.000144	CcSEcCtD
Tizanidine—Abdominal pain—Capecitabine—prostate cancer	3.57e-05	0.000144	CcSEcCtD
Tizanidine—Vomiting—Etoposide—prostate cancer	3.57e-05	0.000144	CcSEcCtD
Tizanidine—Anaemia—Epirubicin—prostate cancer	3.56e-05	0.000144	CcSEcCtD
Tizanidine—Agitation—Epirubicin—prostate cancer	3.54e-05	0.000143	CcSEcCtD
Tizanidine—Dyspepsia—Prednisone—prostate cancer	3.54e-05	0.000143	CcSEcCtD
Tizanidine—Rash—Etoposide—prostate cancer	3.54e-05	0.000143	CcSEcCtD
Tizanidine—Dermatitis—Etoposide—prostate cancer	3.54e-05	0.000143	CcSEcCtD
Tizanidine—Flatulence—Doxorubicin—prostate cancer	3.51e-05	0.000142	CcSEcCtD
Tizanidine—Tension—Doxorubicin—prostate cancer	3.5e-05	0.000141	CcSEcCtD
Tizanidine—Malaise—Epirubicin—prostate cancer	3.48e-05	0.00014	CcSEcCtD
Tizanidine—Fatigue—Prednisone—prostate cancer	3.47e-05	0.00014	CcSEcCtD
Tizanidine—Nervousness—Doxorubicin—prostate cancer	3.46e-05	0.00014	CcSEcCtD
Tizanidine—Vertigo—Epirubicin—prostate cancer	3.46e-05	0.00014	CcSEcCtD
Tizanidine—Syncope—Epirubicin—prostate cancer	3.46e-05	0.000139	CcSEcCtD
Tizanidine—Leukopenia—Epirubicin—prostate cancer	3.45e-05	0.000139	CcSEcCtD
Tizanidine—Back pain—Doxorubicin—prostate cancer	3.45e-05	0.000139	CcSEcCtD
Tizanidine—Constipation—Prednisone—prostate cancer	3.44e-05	0.000139	CcSEcCtD
Tizanidine—Hypersensitivity—Docetaxel—prostate cancer	3.44e-05	0.000139	CcSEcCtD
Tizanidine—Muscle spasms—Doxorubicin—prostate cancer	3.43e-05	0.000138	CcSEcCtD
Tizanidine—Loss of consciousness—Epirubicin—prostate cancer	3.39e-05	0.000137	CcSEcCtD
Tizanidine—Vision blurred—Doxorubicin—prostate cancer	3.36e-05	0.000136	CcSEcCtD
Tizanidine—Asthenia—Docetaxel—prostate cancer	3.35e-05	0.000135	CcSEcCtD
Tizanidine—Convulsion—Epirubicin—prostate cancer	3.34e-05	0.000135	CcSEcCtD
Tizanidine—Nausea—Etoposide—prostate cancer	3.33e-05	0.000134	CcSEcCtD
Tizanidine—Hypertension—Epirubicin—prostate cancer	3.33e-05	0.000134	CcSEcCtD
Tizanidine—Hypersensitivity—Capecitabine—prostate cancer	3.33e-05	0.000134	CcSEcCtD
Tizanidine—Feeling abnormal—Prednisone—prostate cancer	3.32e-05	0.000134	CcSEcCtD
Tizanidine—Ill-defined disorder—Doxorubicin—prostate cancer	3.31e-05	0.000133	CcSEcCtD
Tizanidine—Pruritus—Docetaxel—prostate cancer	3.3e-05	0.000133	CcSEcCtD
Tizanidine—Anaemia—Doxorubicin—prostate cancer	3.3e-05	0.000133	CcSEcCtD
Tizanidine—Gastrointestinal pain—Prednisone—prostate cancer	3.29e-05	0.000133	CcSEcCtD
Tizanidine—Arthralgia—Epirubicin—prostate cancer	3.28e-05	0.000132	CcSEcCtD
Tizanidine—Agitation—Doxorubicin—prostate cancer	3.28e-05	0.000132	CcSEcCtD
Tizanidine—Anxiety—Epirubicin—prostate cancer	3.27e-05	0.000132	CcSEcCtD
Tizanidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.26e-05	0.000131	CcSEcCtD
Tizanidine—Discomfort—Epirubicin—prostate cancer	3.24e-05	0.000131	CcSEcCtD
Tizanidine—Asthenia—Capecitabine—prostate cancer	3.24e-05	0.000131	CcSEcCtD
Tizanidine—Malaise—Doxorubicin—prostate cancer	3.22e-05	0.00013	CcSEcCtD
Tizanidine—Dry mouth—Epirubicin—prostate cancer	3.21e-05	0.000129	CcSEcCtD
Tizanidine—Vertigo—Doxorubicin—prostate cancer	3.2e-05	0.000129	CcSEcCtD
Tizanidine—Syncope—Doxorubicin—prostate cancer	3.2e-05	0.000129	CcSEcCtD
Tizanidine—Urticaria—Prednisone—prostate cancer	3.2e-05	0.000129	CcSEcCtD
Tizanidine—Pruritus—Capecitabine—prostate cancer	3.2e-05	0.000129	CcSEcCtD
Tizanidine—Leukopenia—Doxorubicin—prostate cancer	3.19e-05	0.000129	CcSEcCtD
Tizanidine—Diarrhoea—Docetaxel—prostate cancer	3.19e-05	0.000129	CcSEcCtD
Tizanidine—Body temperature increased—Prednisone—prostate cancer	3.18e-05	0.000128	CcSEcCtD
Tizanidine—Abdominal pain—Prednisone—prostate cancer	3.18e-05	0.000128	CcSEcCtD
Tizanidine—Confusional state—Epirubicin—prostate cancer	3.17e-05	0.000128	CcSEcCtD
Tizanidine—Oedema—Epirubicin—prostate cancer	3.15e-05	0.000127	CcSEcCtD
Tizanidine—Anaphylactic shock—Epirubicin—prostate cancer	3.15e-05	0.000127	CcSEcCtD
Tizanidine—Loss of consciousness—Doxorubicin—prostate cancer	3.14e-05	0.000126	CcSEcCtD
Tizanidine—Infection—Epirubicin—prostate cancer	3.13e-05	0.000126	CcSEcCtD
Tizanidine—Shock—Epirubicin—prostate cancer	3.1e-05	0.000125	CcSEcCtD
Tizanidine—Convulsion—Doxorubicin—prostate cancer	3.09e-05	0.000125	CcSEcCtD
Tizanidine—Diarrhoea—Capecitabine—prostate cancer	3.09e-05	0.000125	CcSEcCtD
Tizanidine—Nervous system disorder—Epirubicin—prostate cancer	3.09e-05	0.000124	CcSEcCtD
Tizanidine—Dizziness—Docetaxel—prostate cancer	3.08e-05	0.000124	CcSEcCtD
Tizanidine—Thrombocytopenia—Epirubicin—prostate cancer	3.08e-05	0.000124	CcSEcCtD
Tizanidine—Hypertension—Doxorubicin—prostate cancer	3.08e-05	0.000124	CcSEcCtD
Tizanidine—Tachycardia—Epirubicin—prostate cancer	3.07e-05	0.000124	CcSEcCtD
Tizanidine—Skin disorder—Epirubicin—prostate cancer	3.06e-05	0.000123	CcSEcCtD
Tizanidine—Hyperhidrosis—Epirubicin—prostate cancer	3.04e-05	0.000123	CcSEcCtD
Tizanidine—Arthralgia—Doxorubicin—prostate cancer	3.04e-05	0.000122	CcSEcCtD
Tizanidine—Anxiety—Doxorubicin—prostate cancer	3.03e-05	0.000122	CcSEcCtD
Tizanidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.02e-05	0.000122	CcSEcCtD
Tizanidine—Discomfort—Doxorubicin—prostate cancer	3e-05	0.000121	CcSEcCtD
Tizanidine—Dizziness—Capecitabine—prostate cancer	2.99e-05	0.00012	CcSEcCtD
Tizanidine—Dry mouth—Doxorubicin—prostate cancer	2.97e-05	0.00012	CcSEcCtD
Tizanidine—Vomiting—Docetaxel—prostate cancer	2.97e-05	0.00012	CcSEcCtD
Tizanidine—Hypersensitivity—Prednisone—prostate cancer	2.96e-05	0.00012	CcSEcCtD
Tizanidine—Rash—Docetaxel—prostate cancer	2.94e-05	0.000119	CcSEcCtD
Tizanidine—Hypotension—Epirubicin—prostate cancer	2.94e-05	0.000119	CcSEcCtD
Tizanidine—Dermatitis—Docetaxel—prostate cancer	2.94e-05	0.000118	CcSEcCtD
Tizanidine—Confusional state—Doxorubicin—prostate cancer	2.94e-05	0.000118	CcSEcCtD
Tizanidine—Anaphylactic shock—Doxorubicin—prostate cancer	2.91e-05	0.000117	CcSEcCtD
Tizanidine—Oedema—Doxorubicin—prostate cancer	2.91e-05	0.000117	CcSEcCtD
Tizanidine—Infection—Doxorubicin—prostate cancer	2.89e-05	0.000117	CcSEcCtD
Tizanidine—Asthenia—Prednisone—prostate cancer	2.89e-05	0.000116	CcSEcCtD
Tizanidine—Vomiting—Capecitabine—prostate cancer	2.87e-05	0.000116	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.87e-05	0.000116	CcSEcCtD
Tizanidine—Shock—Doxorubicin—prostate cancer	2.86e-05	0.000115	CcSEcCtD
Tizanidine—Nervous system disorder—Doxorubicin—prostate cancer	2.85e-05	0.000115	CcSEcCtD
Tizanidine—Thrombocytopenia—Doxorubicin—prostate cancer	2.85e-05	0.000115	CcSEcCtD
Tizanidine—Rash—Capecitabine—prostate cancer	2.85e-05	0.000115	CcSEcCtD
Tizanidine—Pruritus—Prednisone—prostate cancer	2.85e-05	0.000115	CcSEcCtD
Tizanidine—Dermatitis—Capecitabine—prostate cancer	2.84e-05	0.000115	CcSEcCtD
Tizanidine—Tachycardia—Doxorubicin—prostate cancer	2.84e-05	0.000115	CcSEcCtD
Tizanidine—Skin disorder—Doxorubicin—prostate cancer	2.83e-05	0.000114	CcSEcCtD
Tizanidine—Paraesthesia—Epirubicin—prostate cancer	2.83e-05	0.000114	CcSEcCtD
Tizanidine—Hyperhidrosis—Doxorubicin—prostate cancer	2.81e-05	0.000113	CcSEcCtD
Tizanidine—Dyspnoea—Epirubicin—prostate cancer	2.81e-05	0.000113	CcSEcCtD
Tizanidine—Somnolence—Epirubicin—prostate cancer	2.8e-05	0.000113	CcSEcCtD
Tizanidine—Nausea—Docetaxel—prostate cancer	2.77e-05	0.000112	CcSEcCtD
Tizanidine—Dyspepsia—Epirubicin—prostate cancer	2.77e-05	0.000112	CcSEcCtD
Tizanidine—Diarrhoea—Prednisone—prostate cancer	2.75e-05	0.000111	CcSEcCtD
Tizanidine—Hypotension—Doxorubicin—prostate cancer	2.72e-05	0.00011	CcSEcCtD
Tizanidine—Fatigue—Epirubicin—prostate cancer	2.71e-05	0.000109	CcSEcCtD
Tizanidine—Constipation—Epirubicin—prostate cancer	2.69e-05	0.000108	CcSEcCtD
Tizanidine—Nausea—Capecitabine—prostate cancer	2.68e-05	0.000108	CcSEcCtD
Tizanidine—Dizziness—Prednisone—prostate cancer	2.66e-05	0.000107	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.65e-05	0.000107	CcSEcCtD
Tizanidine—Paraesthesia—Doxorubicin—prostate cancer	2.61e-05	0.000105	CcSEcCtD
Tizanidine—Dyspnoea—Doxorubicin—prostate cancer	2.6e-05	0.000105	CcSEcCtD
Tizanidine—Feeling abnormal—Epirubicin—prostate cancer	2.59e-05	0.000105	CcSEcCtD
Tizanidine—Somnolence—Doxorubicin—prostate cancer	2.59e-05	0.000104	CcSEcCtD
Tizanidine—Gastrointestinal pain—Epirubicin—prostate cancer	2.57e-05	0.000104	CcSEcCtD
Tizanidine—Dyspepsia—Doxorubicin—prostate cancer	2.56e-05	0.000103	CcSEcCtD
Tizanidine—Vomiting—Prednisone—prostate cancer	2.56e-05	0.000103	CcSEcCtD
Tizanidine—Rash—Prednisone—prostate cancer	2.54e-05	0.000102	CcSEcCtD
Tizanidine—Dermatitis—Prednisone—prostate cancer	2.53e-05	0.000102	CcSEcCtD
Tizanidine—Fatigue—Doxorubicin—prostate cancer	2.51e-05	0.000101	CcSEcCtD
Tizanidine—Urticaria—Epirubicin—prostate cancer	2.5e-05	0.000101	CcSEcCtD
Tizanidine—Constipation—Doxorubicin—prostate cancer	2.49e-05	0.0001	CcSEcCtD
Tizanidine—Abdominal pain—Epirubicin—prostate cancer	2.49e-05	0.0001	CcSEcCtD
Tizanidine—Body temperature increased—Epirubicin—prostate cancer	2.49e-05	0.0001	CcSEcCtD
Tizanidine—Feeling abnormal—Doxorubicin—prostate cancer	2.4e-05	9.67e-05	CcSEcCtD
Tizanidine—Nausea—Prednisone—prostate cancer	2.39e-05	9.64e-05	CcSEcCtD
Tizanidine—Gastrointestinal pain—Doxorubicin—prostate cancer	2.38e-05	9.6e-05	CcSEcCtD
Tizanidine—Hypersensitivity—Epirubicin—prostate cancer	2.32e-05	9.35e-05	CcSEcCtD
Tizanidine—Urticaria—Doxorubicin—prostate cancer	2.31e-05	9.33e-05	CcSEcCtD
Tizanidine—Abdominal pain—Doxorubicin—prostate cancer	2.3e-05	9.28e-05	CcSEcCtD
Tizanidine—Body temperature increased—Doxorubicin—prostate cancer	2.3e-05	9.28e-05	CcSEcCtD
Tizanidine—Asthenia—Epirubicin—prostate cancer	2.26e-05	9.1e-05	CcSEcCtD
Tizanidine—Pruritus—Epirubicin—prostate cancer	2.23e-05	8.98e-05	CcSEcCtD
Tizanidine—Diarrhoea—Epirubicin—prostate cancer	2.15e-05	8.68e-05	CcSEcCtD
Tizanidine—Hypersensitivity—Doxorubicin—prostate cancer	2.14e-05	8.65e-05	CcSEcCtD
Tizanidine—Asthenia—Doxorubicin—prostate cancer	2.09e-05	8.42e-05	CcSEcCtD
Tizanidine—Dizziness—Epirubicin—prostate cancer	2.08e-05	8.39e-05	CcSEcCtD
Tizanidine—Pruritus—Doxorubicin—prostate cancer	2.06e-05	8.31e-05	CcSEcCtD
Tizanidine—Vomiting—Epirubicin—prostate cancer	2e-05	8.07e-05	CcSEcCtD
Tizanidine—Diarrhoea—Doxorubicin—prostate cancer	1.99e-05	8.03e-05	CcSEcCtD
Tizanidine—Rash—Epirubicin—prostate cancer	1.98e-05	8e-05	CcSEcCtD
Tizanidine—Dermatitis—Epirubicin—prostate cancer	1.98e-05	7.99e-05	CcSEcCtD
Tizanidine—Dizziness—Doxorubicin—prostate cancer	1.93e-05	7.76e-05	CcSEcCtD
Tizanidine—Nausea—Epirubicin—prostate cancer	1.87e-05	7.54e-05	CcSEcCtD
Tizanidine—Vomiting—Doxorubicin—prostate cancer	1.85e-05	7.46e-05	CcSEcCtD
Tizanidine—Rash—Doxorubicin—prostate cancer	1.84e-05	7.4e-05	CcSEcCtD
Tizanidine—Dermatitis—Doxorubicin—prostate cancer	1.83e-05	7.39e-05	CcSEcCtD
Tizanidine—Nausea—Doxorubicin—prostate cancer	1.73e-05	6.97e-05	CcSEcCtD
Tizanidine—ADRA2A—Signaling Pathways—VAV3—prostate cancer	6.87e-06	9.9e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—AKT1—prostate cancer	6.85e-06	9.88e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.85e-06	9.88e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—PIK3CG—prostate cancer	6.8e-06	9.81e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—IL2—prostate cancer	6.78e-06	9.77e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—TGFBR2—prostate cancer	6.77e-06	9.76e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—TERT—prostate cancer	6.75e-06	9.73e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—LEP—prostate cancer	6.75e-06	9.73e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—CAV1—prostate cancer	6.69e-06	9.64e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—ITPR1—prostate cancer	6.66e-06	9.61e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—HPGDS—prostate cancer	6.65e-06	9.59e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—KDR—prostate cancer	6.61e-06	9.53e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP2C19—prostate cancer	6.61e-06	9.53e-05	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—PIK3CB—prostate cancer	6.6e-06	9.52e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—MTHFR—prostate cancer	6.58e-06	9.48e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—HIF1A—prostate cancer	6.46e-06	9.31e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—PPARA—prostate cancer	6.45e-06	9.3e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—ACHE—prostate cancer	6.45e-06	9.3e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—GSTT1—prostate cancer	6.45e-06	9.3e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—ESR1—prostate cancer	6.44e-06	9.29e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—INS—prostate cancer	6.44e-06	9.28e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Hemostasis—AKT1—prostate cancer	6.4e-06	9.23e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP2A6—prostate cancer	6.37e-06	9.19e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—IGF1R—prostate cancer	6.37e-06	9.19e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—PIK3CA—prostate cancer	6.37e-06	9.18e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.35e-06	9.16e-05	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—CXCL8—prostate cancer	6.34e-06	9.14e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—JAK2—prostate cancer	6.31e-06	9.1e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—CREBBP—prostate cancer	6.31e-06	9.09e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—LEP—prostate cancer	6.3e-06	9.09e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—BAD—prostate cancer	6.29e-06	9.07e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—CAV1—prostate cancer	6.24e-06	9e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—AKR1C3—prostate cancer	6.2e-06	8.94e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—KDR—prostate cancer	6.17e-06	8.9e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PRKACB—prostate cancer	6.17e-06	8.89e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—TP53—prostate cancer	6.16e-06	8.88e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—LPL—prostate cancer	6.11e-06	8.81e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP17A1—prostate cancer	6.1e-06	8.8e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—PIK3CG—prostate cancer	6.09e-06	8.78e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—APC—prostate cancer	6.09e-06	8.78e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—CAV1—prostate cancer	6.07e-06	8.75e-05	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—IL2—prostate cancer	6.06e-06	8.74e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—PDGFRB—prostate cancer	6.05e-06	8.73e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.02e-06	8.68e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—IRS1—prostate cancer	6.02e-06	8.68e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—EGF—prostate cancer	6.02e-06	8.68e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—ESR1—prostate cancer	6.02e-06	8.68e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—PIK3CB—prostate cancer	5.99e-06	8.64e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—PIK3CD—prostate cancer	5.98e-06	8.62e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—ITGB3—prostate cancer	5.9e-06	8.5e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—BAD—prostate cancer	5.87e-06	8.47e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—GSK3B—prostate cancer	5.84e-06	8.43e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—NCOA2—prostate cancer	5.82e-06	8.39e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—INS—prostate cancer	5.76e-06	8.31e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—CXCL8—prostate cancer	5.76e-06	8.3e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—ERBB3—prostate cancer	5.72e-06	8.25e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—FGFR2—prostate cancer	5.71e-06	8.24e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—PIK3CG—prostate cancer	5.69e-06	8.2e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—APC—prostate cancer	5.69e-06	8.2e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—NOS3—prostate cancer	5.65e-06	8.14e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—CREBBP—prostate cancer	5.65e-06	8.14e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—EGF—prostate cancer	5.62e-06	8.11e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—IRS1—prostate cancer	5.62e-06	8.11e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—IGF1—prostate cancer	5.58e-06	8.04e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—SLC5A5—prostate cancer	5.55e-06	8e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—EGFR—prostate cancer	5.55e-06	8e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—PIK3CG—prostate cancer	5.53e-06	7.97e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—IL2—prostate cancer	5.5e-06	7.94e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—TERT—prostate cancer	5.48e-06	7.91e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—GSK3B—prostate cancer	5.46e-06	7.87e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP2E1—prostate cancer	5.42e-06	7.82e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—MAP2K1—prostate cancer	5.39e-06	7.77e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—INS—prostate cancer	5.38e-06	7.76e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—NQO1—prostate cancer	5.36e-06	7.73e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—PIK3CD—prostate cancer	5.35e-06	7.72e-05	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—PIK3CA—prostate cancer	5.3e-06	7.65e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—SERPINE1—prostate cancer	5.29e-06	7.63e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—TH—prostate cancer	5.28e-06	7.62e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—CREBBP—prostate cancer	5.27e-06	7.6e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.25e-06	7.57e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	5.24e-06	7.56e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—KRAS—prostate cancer	5.24e-06	7.56e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—INS—prostate cancer	5.23e-06	7.54e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP3A4—prostate cancer	5.23e-06	7.54e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—PIK3CB—prostate cancer	5.21e-06	7.52e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—IGF1—prostate cancer	5.21e-06	7.51e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—AKT1—prostate cancer	5.2e-06	7.5e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.2e-06	7.5e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—EGFR—prostate cancer	5.18e-06	7.47e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—PTGS2—prostate cancer	5.16e-06	7.45e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP1B1—prostate cancer	5.14e-06	7.41e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—FGF2—prostate cancer	5.13e-06	7.39e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—CREBBP—prostate cancer	5.12e-06	7.39e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—LEP—prostate cancer	5.12e-06	7.38e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—CAV1—prostate cancer	5.07e-06	7.31e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—NOS3—prostate cancer	5.06e-06	7.29e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—MAP2K1—prostate cancer	5.03e-06	7.26e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—KDR—prostate cancer	5.02e-06	7.23e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—PIK3CD—prostate cancer	5e-06	7.21e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—GGT1—prostate cancer	4.98e-06	7.18e-05	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—PIK3CA—prostate cancer	4.95e-06	7.14e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	4.95e-06	7.13e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—JAK2—prostate cancer	4.91e-06	7.08e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—NCOA1—prostate cancer	4.9e-06	7.07e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	4.9e-06	7.06e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—ESR1—prostate cancer	4.89e-06	7.05e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—PIK3CD—prostate cancer	4.86e-06	7e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP19A1—prostate cancer	4.83e-06	6.97e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—PIK3CA—prostate cancer	4.82e-06	6.94e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—MDM2—prostate cancer	4.8e-06	6.91e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—FGF2—prostate cancer	4.79e-06	6.9e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—BAD—prostate cancer	4.77e-06	6.88e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—ERBB2—prostate cancer	4.73e-06	6.82e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—NOS3—prostate cancer	4.72e-06	6.81e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	4.67e-06	6.73e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—RXRA—prostate cancer	4.66e-06	6.72e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—APC—prostate cancer	4.62e-06	6.66e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	4.62e-06	6.66e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—JAK2—prostate cancer	4.59e-06	6.62e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—NOS3—prostate cancer	4.59e-06	6.61e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—IRS1—prostate cancer	4.57e-06	6.58e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—EGF—prostate cancer	4.57e-06	6.58e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.54e-06	6.54e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—PTEN—prostate cancer	4.5e-06	6.49e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	4.5e-06	6.49e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—COMT—prostate cancer	4.49e-06	6.48e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	4.48e-06	6.47e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—MDM2—prostate cancer	4.48e-06	6.46e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—GSTP1—prostate cancer	4.47e-06	6.45e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	4.43e-06	6.39e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	4.42e-06	6.37e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—ITPR1—prostate cancer	4.4e-06	6.34e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	4.38e-06	6.31e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—INS—prostate cancer	4.37e-06	6.31e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	4.36e-06	6.28e-05	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	4.33e-06	6.25e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.32e-06	6.24e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—EP300—prostate cancer	4.3e-06	6.19e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—CASP3—prostate cancer	4.29e-06	6.19e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—IL2—prostate cancer	4.29e-06	6.18e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	4.28e-06	6.18e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—IL6—prostate cancer	4.26e-06	6.15e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—PIK3CB—prostate cancer	4.23e-06	6.1e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—IGF1—prostate cancer	4.23e-06	6.1e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	4.21e-06	6.07e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—PTGS2—prostate cancer	4.2e-06	6.05e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	4.19e-06	6.04e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—CCND1—prostate cancer	4.18e-06	6.02e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—TYMS—prostate cancer	4.16e-06	5.99e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	4.14e-06	5.96e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—GSTM1—prostate cancer	4.11e-06	5.92e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	4.09e-06	5.9e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	4.09e-06	5.9e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	4.06e-06	5.86e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—MMP9—prostate cancer	4.06e-06	5.85e-05	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	4.05e-06	5.83e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	4.04e-06	5.83e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—LPL—prostate cancer	4.03e-06	5.81e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—PTEN—prostate cancer	4.03e-06	5.81e-05	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	4.02e-06	5.8e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	4.02e-06	5.79e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—CASP3—prostate cancer	4.01e-06	5.78e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—IL2—prostate cancer	4e-06	5.77e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—IL6—prostate cancer	3.98e-06	5.74e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	3.98e-06	5.73e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	3.93e-06	5.67e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—CCND1—prostate cancer	3.9e-06	5.63e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP1A1—prostate cancer	3.89e-06	5.61e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	3.89e-06	5.61e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	3.86e-06	5.57e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—ERCC2—prostate cancer	3.86e-06	5.57e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—EP300—prostate cancer	3.85e-06	5.54e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	3.84e-06	5.53e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—MMP9—prostate cancer	3.79e-06	5.46e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	3.77e-06	5.44e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—PTEN—prostate cancer	3.77e-06	5.43e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—SRC—prostate cancer	3.74e-06	5.39e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	3.73e-06	5.37e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	3.67e-06	5.3e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—PTEN—prostate cancer	3.66e-06	5.28e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	3.65e-06	5.27e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	3.64e-06	5.25e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	3.64e-06	5.25e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—MTHFR—prostate cancer	3.63e-06	5.23e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	3.61e-06	5.2e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—EP300—prostate cancer	3.59e-06	5.18e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	3.59e-06	5.17e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PPARA—prostate cancer	3.56e-06	5.14e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	3.54e-06	5.1e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—SRC—prostate cancer	3.49e-06	5.04e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—EP300—prostate cancer	3.49e-06	5.03e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	3.4e-06	4.91e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	3.4e-06	4.9e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	3.37e-06	4.86e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—MYC—prostate cancer	3.35e-06	4.83e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CAV1—prostate cancer	3.35e-06	4.83e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	3.34e-06	4.82e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	3.32e-06	4.79e-05	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	3.29e-06	4.74e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	3.28e-06	4.73e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	3.26e-06	4.69e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—IL2—prostate cancer	3.25e-06	4.69e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	3.24e-06	4.66e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.2e-06	4.61e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—PIK3CA—prostate cancer	3.18e-06	4.58e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	3.17e-06	4.57e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	3.14e-06	4.53e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—MYC—prostate cancer	3.13e-06	4.51e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	3.12e-06	4.5e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	3.1e-06	4.46e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	3.08e-06	4.44e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	3.07e-06	4.42e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	3.06e-06	4.41e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	3.06e-06	4.41e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PIK3CG—prostate cancer	3.05e-06	4.4e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	2.98e-06	4.3e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—EP300—prostate cancer	2.92e-06	4.21e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	2.89e-06	4.17e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—INS—prostate cancer	2.89e-06	4.16e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	2.84e-06	4.1e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—SRC—prostate cancer	2.84e-06	4.09e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CREBBP—prostate cancer	2.83e-06	4.08e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	2.76e-06	3.98e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—TP53—prostate cancer	2.75e-06	3.97e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	2.74e-06	3.94e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PIK3CD—prostate cancer	2.68e-06	3.87e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	2.66e-06	3.83e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—AKT1—prostate cancer	2.6e-06	3.74e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—PIK3CA—prostate cancer	2.58e-06	3.72e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—TP53—prostate cancer	2.57e-06	3.71e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—MYC—prostate cancer	2.54e-06	3.67e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	2.54e-06	3.66e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—NOS3—prostate cancer	2.53e-06	3.65e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—IL6—prostate cancer	2.52e-06	3.63e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	2.49e-06	3.59e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—IL6—prostate cancer	2.35e-06	3.39e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	2.35e-06	3.39e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PIK3CB—prostate cancer	2.34e-06	3.37e-05	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	2.32e-06	3.35e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PTGS2—prostate cancer	2.32e-06	3.34e-05	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	2.17e-06	3.13e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	2.16e-06	3.11e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—AKT1—prostate cancer	2.11e-06	3.04e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—TP53—prostate cancer	2.09e-06	3.01e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PTEN—prostate cancer	2.02e-06	2.91e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—EP300—prostate cancer	1.93e-06	2.78e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.91e-06	2.76e-05	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1.76e-06	2.54e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.42e-06	2.05e-05	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—AKT1—prostate cancer	1.16e-06	1.68e-05	CbGpPWpGaD
